BioAtla Investor Presentation Deck
Phase 2 CAB-AXL (BA3011): Summary of Treatment Emergent Adverse Events
(Non-Squamous NSCLC)
bicatla
TEAEs with CTCAE grade 3 or 4
Related grade 3 or 4 AEs
Any serious TEAES
Related SAEs
TEAEs leading to treatment d/c
Related AEs leading to treatment d/c
TEAES leading to death
Related AEs leading to death
BA3011
monotherapy
(n=23)
15 (65.2)
8 (34.8)
9 (39.1)
3 (13.0)
1 (4.3)
1 (4.3)
Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer
2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL.
0
0
Data Cut Date: 30Jun23
BA3011 +
nivolumab
(n=17)
8 (47.1)
3 (17.6)
5 (29.4)
1 (5.9)
1 (5.9)
1 (5.9)
1 (5.9)
0
Total
(N=40)
23 (57.5)
11 (27.5)
14 (35.0)
4 (10.0)
2 (5.0)
2 (5.0)
1 (2.5)
0
BioAtla| Overview
37View entire presentation